Analysts Offer Predictions for PVLA FY2025 Earnings

Palvella Therapeutics (NASDAQ:PVLA) – Equities research analysts at Chardan Capital issued their FY2025 EPS estimates for shares of Palvella Therapeutics in a research note issued to investors on Wednesday, April 9th. Chardan Capital analyst G. Livshits expects that the company will post earnings of ($2.43) per share for the year. Chardan Capital currently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Palvella Therapeutics’ current full-year earnings is ($3.69) per share. Chardan Capital also issued estimates for Palvella Therapeutics’ FY2026 earnings at ($3.06) EPS.

A number of other research firms have also commented on PVLA. Cantor Fitzgerald assumed coverage on Palvella Therapeutics in a research report on Wednesday, December 18th. They set an “overweight” rating on the stock. Scotiabank began coverage on Palvella Therapeutics in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $50.00 price objective on the stock. Jones Trading started coverage on shares of Palvella Therapeutics in a research report on Tuesday, March 25th. They set a “buy” rating and a $45.00 price target for the company. Canaccord Genuity Group reissued a “buy” rating and issued a $39.00 price target on shares of Palvella Therapeutics in a research note on Wednesday, February 26th. Finally, TD Cowen initiated coverage on Palvella Therapeutics in a report on Wednesday, February 5th. They issued a “buy” rating and a $44.00 price objective for the company. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $44.43.

Palvella Therapeutics Stock Down 2.1 %

NASDAQ PVLA opened at $23.93 on Monday. Palvella Therapeutics has a 1-year low of $6.20 and a 1-year high of $29.27. The firm’s 50 day moving average is $22.94. The firm has a market capitalization of $263.68 million, a P/E ratio of -1.98 and a beta of 0.10.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of PVLA. Suvretta Capital Management LLC acquired a new stake in Palvella Therapeutics in the 4th quarter worth about $8,574,000. BVF Inc. IL bought a new position in Palvella Therapeutics in the 4th quarter valued at about $8,359,000. Samsara BioCapital LLC bought a new stake in shares of Palvella Therapeutics during the 4th quarter worth approximately $8,154,000. Frazier Life Sciences Management L.P. acquired a new position in Palvella Therapeutics during the fourth quarter valued at approximately $7,847,000. Finally, Adams Street Partners LLC bought a new stake in shares of Palvella Therapeutics during the 4th quarter worth $4,916,000. 40.11% of the stock is owned by institutional investors.

Insider Activity

In other news, Director George M. Jenkins acquired 2,500 shares of the stock in a transaction dated Wednesday, April 9th. The shares were bought at an average cost of $20.13 per share, for a total transaction of $50,325.00. Following the purchase, the director now directly owns 183,171 shares of the company’s stock, valued at approximately $3,687,232.23. This trade represents a 1.38 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 6.39% of the stock is owned by corporate insiders.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.